Pharmacokinetics of golimumab in moderate to severe ulcerative colitis: the GO-KINETIC study

A Real-life Population Pharmacokinetic Study Reveals Factors Associated with Clearance and Immunogenicity of Infliximab in Inflammatory Bowel Disease

(2017) Johannan F. Brandse et al.   INFLAMMATORY BOWEL DISEASES

P226 Comparison of four different immunoassays for measuring golimumab and anti-golimumab antibody concentration in patients with ulcerative colitis

(2017) S. Paul et al.   Journal of Crohns & Colitis

Induction infliximab levels among patients with acute severe ulcerative colitis compared with patients with moderately severe ulcerative colitis

(2016) B. Ungar et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Infliximab Concentration Thresholds During Induction Therapy Are Associated With Short-term Mucosal Healing in Patients With Ulcerative Colitis

(2016) Konstantinos Papamichael et al.   Clinical Gastroenterology and Hepatology

Variability in Golimumab Exposure: A ‘Real-Life’ Observational Study in Active Ulcerative Colitis

(2016) Iris Detrez et al.   Journal of Crohns & Colitis

Pharmacokinetics and Exposure-response Relationship of Golimumab in Patients with Moderately-to-Severely Active Ulcerative Colitis: Results from Phase 2/3 PURSUIT Induction and Maintenance Studies

(2016) Omoniyi J. Adedokun et al.   Journal of Crohns & Colitis

Randomised clinical trial: a placebo-controlled study of intravenous golimumab induction therapy for ulcerative colitis

(2015) P. Rutgeerts et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

An Accelerated Infliximab Induction Regimen Reduces the Need for Early Colectomy in Patients With Acute Severe Ulcerative Colitis

(2015) David J. Gibson et al.   Clinical Gastroenterology and Hepatology

Loss of Infliximab Into Feces Is Associated With Lack of Response to Therapy in Patients With Severe Ulcerative Colitis

(2015) Johannan F. Brandse et al.   GASTROENTEROLOGY

The association of tissue anti-TNF drug levels with serological and endoscopic disease activity in inflammatory bowel disease: the ATLAS study

(2015) Andres J Yarur et al.   GUT

The antibody response against human and chimeric anti-TNF therapeutic antibodies primarily targets the TNF binding region

(2014) K A van Schie et al.   ANNALS OF THE RHEUMATIC DISEASES

Golimumab trough levels, antidrug antibodies and clinical response in patients with rheumatoid arthritis treated in daily clinical practice

(2014) Eva L Kneepkens et al.   ANNALS OF THE RHEUMATIC DISEASES

Association Between Serum Concentration of Infliximab and Efficacy in Adult Patients With Ulcerative Colitis

(2014) Omoniyi J. Adedokun et al.   GASTROENTEROLOGY

Patient Factors That Increase Infliximab Clearance and Shorten Half-life in Inflammatory Bowel Disease

(2014) Iris Dotan et al.   INFLAMMATORY BOWEL DISEASES

Subcutaneous Golimumab Induces Clinical Response and Remission in Patients With Moderate-to-Severe Ulcerative Colitis

(2013) William J. Sandborn et al.   GASTROENTEROLOGY

Subcutaneous Golimumab Maintains Clinical Response in Patients With Moderate-to-Severe Ulcerative Colitis

(2013) William J. Sandborn et al.   GASTROENTEROLOGY

Pharmacokinetic Properties of Infliximab in Children and Adults with Crohn's Disease: A Retrospective Analysis of Data from 2 Phase III Clinical Trials

(2011) Adedigbo A. Fasanmade et al.   CLINICAL THERAPEUTICS

Development of Antidrug Antibodies Against Adalimumab and Association With Disease Activity and Treatment Failure During Long-term Follow-up

(2011) Geertje M. Bartelds   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis

(2009) C H Seow et al.   GUT